Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPTX |
---|---|---|
09:32 ET | 7001 | 3.84 |
09:36 ET | 500 | 3.86 |
09:38 ET | 100 | 3.885 |
09:39 ET | 558 | 3.9199 |
09:41 ET | 4894 | 3.94 |
09:45 ET | 117 | 3.9299 |
09:52 ET | 300 | 3.885 |
09:56 ET | 1949 | 3.8614 |
09:57 ET | 380 | 3.9 |
10:06 ET | 200 | 3.885 |
10:10 ET | 270 | 3.8614 |
10:12 ET | 6726 | 3.88 |
10:14 ET | 100 | 3.89 |
10:15 ET | 600 | 3.89 |
10:17 ET | 1899 | 3.9 |
10:19 ET | 100 | 3.9 |
10:24 ET | 858 | 3.9 |
10:26 ET | 125 | 3.9001 |
10:28 ET | 2930 | 3.925 |
10:32 ET | 100 | 3.9 |
10:33 ET | 100 | 3.91 |
10:35 ET | 300 | 3.915 |
10:42 ET | 100 | 3.91 |
10:46 ET | 200 | 3.9 |
10:50 ET | 4589 | 3.905 |
10:53 ET | 920 | 3.91 |
10:55 ET | 390 | 3.91 |
11:00 ET | 600 | 3.92 |
11:02 ET | 100 | 3.91 |
11:04 ET | 300 | 3.92 |
11:06 ET | 100 | 3.91 |
11:08 ET | 700 | 3.91 |
11:09 ET | 1680 | 3.9 |
11:13 ET | 200 | 3.895 |
11:20 ET | 100 | 3.895 |
11:24 ET | 296 | 3.9086 |
11:26 ET | 100 | 3.895 |
11:36 ET | 1383 | 3.895 |
11:42 ET | 843 | 3.8914 |
11:44 ET | 200 | 3.9 |
11:45 ET | 100 | 3.89 |
11:51 ET | 5000 | 3.9 |
11:54 ET | 300 | 3.9 |
11:56 ET | 100 | 3.9 |
11:58 ET | 100 | 3.9 |
12:12 ET | 2200 | 3.9 |
12:14 ET | 520 | 3.9 |
12:16 ET | 100 | 3.9 |
12:21 ET | 100 | 3.89 |
12:30 ET | 216 | 3.9 |
12:32 ET | 600 | 3.89 |
12:34 ET | 100 | 3.89 |
12:36 ET | 100 | 3.89 |
12:38 ET | 100 | 3.89 |
12:39 ET | 1700 | 3.87 |
12:41 ET | 700 | 3.89 |
12:43 ET | 500 | 3.86 |
12:50 ET | 2815 | 3.8104 |
12:52 ET | 200 | 3.81 |
12:54 ET | 800 | 3.82 |
12:57 ET | 100 | 3.82 |
01:03 ET | 100 | 3.82 |
01:08 ET | 100 | 3.82 |
01:12 ET | 1700 | 3.82 |
01:14 ET | 100 | 3.83 |
01:15 ET | 1700 | 3.82 |
01:17 ET | 200 | 3.82 |
01:19 ET | 100 | 3.82 |
01:21 ET | 426 | 3.82 |
01:24 ET | 100 | 3.835 |
01:26 ET | 8469 | 3.9 |
01:28 ET | 100 | 3.885 |
01:30 ET | 600 | 3.9 |
01:33 ET | 100 | 3.895 |
01:37 ET | 900 | 3.9 |
01:39 ET | 100 | 3.89 |
01:44 ET | 500 | 3.88 |
01:48 ET | 100 | 3.89 |
01:50 ET | 100 | 3.89 |
01:53 ET | 400 | 3.87 |
01:55 ET | 100 | 3.885 |
01:57 ET | 664 | 3.885 |
02:00 ET | 340 | 3.8976 |
02:06 ET | 1308 | 3.875 |
02:27 ET | 216 | 3.8809 |
02:40 ET | 300 | 3.86 |
02:45 ET | 100 | 3.83 |
02:47 ET | 100 | 3.831 |
02:49 ET | 200 | 3.85 |
02:54 ET | 300 | 3.86 |
03:00 ET | 852 | 3.81 |
03:05 ET | 618 | 3.82 |
03:07 ET | 1800 | 3.815 |
03:09 ET | 700 | 3.79 |
03:12 ET | 1898 | 3.76 |
03:14 ET | 300 | 3.75 |
03:16 ET | 200 | 3.73 |
03:18 ET | 427 | 3.765 |
03:20 ET | 850 | 3.77 |
03:21 ET | 1935 | 3.77 |
03:30 ET | 100 | 3.78 |
03:41 ET | 100 | 3.775 |
03:48 ET | 5862 | 3.835 |
03:50 ET | 2116 | 3.86 |
03:52 ET | 100 | 3.8401 |
03:54 ET | 460 | 3.84 |
03:56 ET | 400 | 3.845 |
03:57 ET | 14902 | 3.89 |
03:59 ET | 10044 | 3.88 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Repare Therapeutics Inc | 170.6M | -3.5x | --- |
AVITA Medical Inc | 245.4M | -5.2x | --- |
Precision BioSciences Inc | 90.1M | -2.2x | --- |
Metagenomi Inc | 245.4M | -3.3x | --- |
Champions Oncology Inc | 62.7M | -6.4x | --- |
Caribou Biosciences Inc | 191.5M | -1.3x | --- |
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $170.6M |
---|---|
Revenue (TTM) | $97.9M |
Shares Outstanding | 42.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.74 |
EPS | $-1.10 |
Book Value | $5.03 |
P/E Ratio | -3.5x |
Price/Sales (TTM) | 1.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -72.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.